LANTHANUM CARBONATE | A090977 | BARR LABORATORIES INC A WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Shire Development Inc. (Shire) - Citizen Petition FDA-2010-P-0309 · 7 docket documents Shire Development Inc. filed this citizen petition under sections 505(j) and 505(q) requesting that the FDA require all abbreviated new drug applications and 505(b)(2) new drug applications for generic or follow-on formulations of Fosrenol (lanthanum carbonate) oral chewable tablets to include chara | 505(q) | 2010-07-08 | Partially Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$3.25
per ea
Lowest NADAC/Unit
$3.00
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093594098LANTHANUM CARB 1,000 MG TB CHW | $3.25 | EA | Generic | — | 2026-06-17 |
| 00093593898LANTHANUM CARB 500 MG TAB CHEW | $3.00 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.